Crinetics Pharmaceuticals ROE 2024

Crinetics Pharmaceuticals Aktienanalyse

Šta radi Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals Inc. is a leading biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare endocrine diseases and hormone-dependent tumors. The company was founded in 2008 by a team of experienced pharmacy professionals and is headquartered in San Diego, California. History Crinetics Pharmaceuticals was founded based on groundbreaking research in the field of endocrine diseases. The company aims to develop innovative therapies for rare endocrine diseases and hormone-dependent tumors that have been inadequately treated thus far. Crinetics draws on decades of experience and in-depth knowledge in the fields of endocrinology, neuroscience, and cancer research. Business model Crinetics is a research and development company specializing in the discovery, development, and commercialization of drugs for rare endocrine diseases. The company has an extensive portfolio of proprietary compounds based on novel mechanisms of action that are in various stages of development. Crinetics works closely with leading experts in the field of endocrinology and oncology to develop and commercialize groundbreaking new therapies. Different divisions Crinetics specializes in the research, development, and commercialization of products that can be used in rare endocrine diseases and hormone-dependent tumors. The company operates in various areas, including: - Acromegaly: Crinetics is developing a medication for the treatment of acromegaly, a rare disease caused by overproduction of growth hormone. - Cushing's syndrome: Crinetics is developing a medication for the treatment of Cushing's syndrome, a rare disease caused by overproduction of cortisol. - Hypoparathyroidism: Crinetics is developing a medication for the treatment of hypoparathyroidism, a rare disease characterized by insufficient production of parathyroid hormone. - Neuroendocrine tumors: Crinetics is developing a medication for the treatment of neuroendocrine tumors, a rare group of tumors that arise from neuroendocrine cells. Products Crinetics has an extensive portfolio of innovative products based on novel mechanisms of action that are in various stages of development. The company focuses on developing drugs that can be used in rare endocrine diseases and hormone-dependent tumors. Some of the notable products are: - CRN00808: CRN00808 is a medication that can help improve the body's monitoring system that regulates the release of growth hormones. It is currently in phase 2 clinical trials. - CRN01941: CRN01941 is a medication for the treatment of Cushing's syndrome. It has been developed to inhibit excessive production of cortisol and is currently in phase 2 clinical trials. - CRN04777: CRN04777 is a medication for the treatment of acromegaly. It has been developed to inhibit overproduction of growth hormone and is currently in phase 1 clinical trials. - CRN04894: CRN04894 is a medication for the treatment of hypoparathyroidism. It has been developed to stimulate parathyroid hormone production and is currently in phase 1 clinical trials. Conclusion Crinetics Pharmaceuticals is a leading biopharmaceutical company specializing in the development of innovative therapies for rare endocrine diseases and hormone-dependent tumors. The company has an extensive portfolio of proprietary compounds based on novel mechanisms of action that are in various stages of development. Crinetics works closely with leading experts in the field of endocrinology and oncology to develop and commercialize groundbreaking new therapies. Crinetics Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE у детаљу

Razjašnjenje povrata na sopstveni kapital (ROE) kompanije Crinetics Pharmaceuticals

Povraćaj na sopstveni kapital (ROE) kompanije Crinetics Pharmaceuticals je osnovni pokazatelj koji ocenjuje profitabilnost kompanije u odnosu na sopstveni kapital. ROE, izračunat deljenjem neto dobiti sa sopstvenim kapitalom akcionara, ilustruje efikasnost kompanije u ostvarivanju profita iz investicija akcionara. Viši ROE označava povećanu efikasnost i profitabilnost.

Poređenje iz godine u godinu

Analiza ROE kompanije Crinetics Pharmaceuticals iz godine u godinu pomaže u praćenju trendova profitabilnosti i finansijskih performansi. Rastući ROE ukazuje na povećanu profitabilnost i stvaranje vrednosti za akcionare, dok opadajući ROE može ukazivati na probleme u stvaranju dobiti ili upravljanju sopstvenim kapitalom.

Uticaj na investicije

ROE kompanije Crinetics Pharmaceuticals je ključan za investitore koji ocenjuju profitabilnost, efikasnost i privlačnost kompanije kao investicije. Robusni ROE ukazuje na sposobnost kompanije da pretvori investicije sopstvenog kapitala u profit, čime povećava svoju privlačnost potencijalnim i sadašnjim investitorima.

Interpretacija fluktuacija ROE

Promene u ROE kompanije Crinetics Pharmaceuticals mogu proizaći iz fluktuacija neto dobiti, sopstvenog kapitala ili oboje. Ove fluktuacije se analiziraju sa ciljem procene efikasnosti menadžmenta, finansijskih strategija, kao i povezanih rizika i mogućnosti, te pomažu investitorima u donošenju obrazloženih odluka.

Često postavljana pitanja o Crinetics Pharmaceuticals akciji

Koliki je ROE (Return on Equity) kompanije Crinetics Pharmaceuticals ove godine?

ROE kompanije Crinetics Pharmaceuticals u ovoj godini iznosi -0,40 undefined.

Kako se ROE (Return on Equity) kompanije Crinetics Pharmaceuticals razvio u poređenju sa prethodnom godinom?

ROE kompanije Crinetics Pharmaceuticals se u poređenju sa prošlom godinom promenio za -23,21% pao.

Kakav uticaj visoki ROE (povraćaj na kapital) ima na investitore Crinetics Pharmaceuticals?

Visok ROE pokazuje da Crinetics Pharmaceuticals postiže dobar povraćaj kapitala i da je uspešan u monetizaciji svojih investicija. Ovo je za investitore pozitivan indikator.

Koji uticaj ima nizak ROE (Povraćaj na kapital) na investitore Crinetics Pharmaceuticals?

Nizak ROE može ukazivati na to da Crinetics Pharmaceuticals ima poteškoće u uspešnom monetizovanju svojih investicija i može biti negativan signal za investitore.

Kako promena ROE (Return on Equity) od Crinetics Pharmaceuticals utiče na preduzeće?

Promena ROE (povraćaja na kapital) od Crinetics Pharmaceuticals može biti indikator finansijske performanse kompanije i pokazati koliko je uspešna u odnosu na druge kompanije u istoj industriji.

Kako se izračunava ROE (Povraćaj na sopstveni kapital) od Crinetics Pharmaceuticals?

ROE (Return on Equity) se izračunava tako što se dobit preduzeća podeli sa ukupnim kapitalom. Formula glasi: ROE = Dobit / Ukupni kapital.

Koji faktori utiču na ROE (Return on Equity) kompanije Crinetics Pharmaceuticals?

Neki faktori koji mogu uticati na ROE (Return on Equity) kompanije Crinetics Pharmaceuticals uključuju, između ostalih, efikasnost u korišćenju sopstvenog kapitala, profitabilnost preduzeća i strukturu finansiranja.

Koje strateške mere može preduzeti da poboljša ROE (povrat na kapital)?

Da bi poboljšao ROE (Return on Equity), može preduzeti različite mere kao što su smanjenje troškova, povećanje prihoda, poboljšanje efikasnosti korišćenja kapitala i promene u strukturi finansiranja. Važno je da kompanija izvrši temeljnu proveru svoje finansijske situacije kako bi odredila najbolje strateške mere za poboljšanje ROE (Return on Equity).

Kolika je dividenda koju isplaćuje Crinetics Pharmaceuticals?

U poslednjih 12 meseci, Crinetics Pharmaceuticals je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Crinetics Pharmaceuticals će verovatno isplatiti dividendu od 0 USD.

Kolika je dividendna prinosa za Crinetics Pharmaceuticals?

Dividendski prinos od Crinetics Pharmaceuticals trenutno iznosi .

Kada Crinetics Pharmaceuticals isplaćuje dividendu?

Crinetics Pharmaceuticals isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije Crinetics Pharmaceuticals?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von Crinetics Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od Crinetics Pharmaceuticals od 30. 9. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 30. 9. 2024..

Kada je Crinetics Pharmaceuticals poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 30. 9. 2024..

Kolika je bila dividenda od Crinetics Pharmaceuticals u godini 2023?

U godini 2023 kompanija Crinetics Pharmaceuticals je isplatila 0 USD kao dividende.

U kojoj valuti Crinetics Pharmaceuticals isplaćuje dividendu?

Dividende od Crinetics Pharmaceuticals se isplaćuju u USD.